Carbon Capture and Storage (CCS) Market – Trends Forecast Till 2030 (1)

1
Central Nervous System (CNS) Therapeutics Market
Trends, Size, Share, Demands, Overview, Growth,
Revenue and Forecast to 2030
sales_at_delvens.com www.delvens.com
2

Central Nervous System (CNS) Therapeutics Market,
by Disease (Neurovascular Diseases, Trauma,
Mental Health, Degenerative Disease, Infectious
Diseases, Cancer, and Others), Drug Class
(Analgesics, Antidepressants, Anaesthetics,
Anti-Parkinson Drugs, Anti-Epileptics, and Other
Drug Classes), Distribution Channel
(Hospital-based Pharmacies, Retail-based
Pharmacies, and Online Pharmacies), Age Group
(Paediatric, Adult, Geriatric), and region (North
America, Europe, Asia-Pacific, Middle East and
Africa and South America).

Request For Free Sample Report
https//www.delvens.com/get-free-sample/central-ne
rvous-system-therapeutics-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Central Nervous System (CNS) therapeutics are
drugs that are used to treat diseases of the
brain and spinal cord. They are a broad class of
drugs that include many different types, each
with its own specific mechanism of action. The
CNS includes the brain and spinal cord and plays
a crucial role in controlling various bodily
functions and behaviours. CNS therapeutics are
used to treat a wide range of neurological and
psychiatric conditions. Some common CNS
therapeutics include antidepressants, which are
used to treat depression and certain anxiety
disorders, anti-epileptics, which are used to
control seizures and are essential in the
treatment of epilepsy, antipsychotics, which are
used to manage psychotic disorders like
schizophrenia and bipolar disorders, etc. CNS
therapeutics play a crucial role in improving the
quality of individuals with various neurological
and psychiatric conditions. Purchase this
Report https//www.delvens.com/checkout/central-n
ervous-system-therapeutics-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
The Central Nervous System (CNS) Therapeutics
Market is segmented into various segments such as
disease, drug class, distribution channel, age
group and region Based on drug class, the
market is segmented into analgesics,
antidepressants, anaesthetics, anti-Parkinson
drugs, anti-epileptics, and other drug classes.
The antidepressants segment led the CNS
therapeutics market in this segment and is
expected to dominate the market during the
forecast period due to increasing prevalence of
depression and the rising demand for effective
treatments.  Based on distribution channel, the
market can be segmented into hospital-based
pharmacies, retail-based pharmacies and online
pharmacies. The hospital-based pharmacies
dominated the market in this segment due to rapid
increase in prevalence of CNS diseases in
geriatric population, technological advancements
and lifestyle changes.  By age group, the market
is segmented into paediatric, adult and
geriatric. The geriatric population dominated the
market in this segment and is expected to
dominate the market during the forecast period.
This is due to the rapid increase in CNS diseases
such as Alzheimers in the geriatric population.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The market is also divided into various regions
such as North America, Europe, Asia-Pacific,
South America, and Middle East and Africa. North
America is estimated to account for the largest
market share during the forecast period. Inquire
Before Buying https//www.delvens.com/Inquire-bef
ore-buying/central-nervous-system-therapeutics-mar
ket
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Biogen
• Otsuka Pharmaceutical Co. Ltd
• Eli Lilly and Company
• Merck KGaA
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Johnson Johnson Private Limited
• Pfizer Inc.
• GlaxoSmithKline PLC

• Shire PLC
• Cipla Inc.
• Lupin Ltd
• Glenmark Pharmaceuticals
• AbbVie Inc.
• BIAL Group
• Bristol-Myers Squibb
• Allergan Plc
• Alkermes Plc

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In June 2022, CNS Pharmaceuticals, Inc. received
approval from the U.S. Food and Drug
Administration (FDA) for its ongoing potentially
pivotal global study evaluating the efficacy and
safety of Berubicin compared with Lomustine
(Gleostine) administered after first-line therapy
for the treatment of recurrent glioblastoma
multiforme (GBM), one of the most aggressive
types of brain cancer.  In January 2022, Otsuka
Pharmaceutical Co., Ltd. (Otsuka) its subsidiary
Otsuka America Pharmaceutical, Inc. and
Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck
A/S in Denmark, announced that the U.S. Food and
Drug Administration (FDA) has approved the
supplemental new drug application (sNDA) of
REXULTI (brexpiprazole) for the treatment of
schizophrenia in paediatric patients 13 to 17
years of age.
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com